Last reviewed · How we verify
Gbt021601 (gbt021601)
GBT021601, developed by Pfizer Inc., is a marketed drug used to treat severe hemophilia A with inhibitors. It has generated $21.2B in revenue. The drug's mechanism is not specified. GBT021601 has 6 trials and 0 publications. Its key indication is the treatment of adult patients with severe hemophilia A with inhibitors. The drug's clinical differentiation and commercial significance are not provided. There are no pipeline developments mentioned.
At a glance
| Generic name | gbt021601 |
|---|---|
| Sponsor | Pfizer |
| Drug class | unknown |
| Target | unknown |
| Therapeutic area | Rare Disease |
| Phase | FDA-approved |
Approved indications
- Treatment of adult patients with severe hemophilia A with inhibitors
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pentobarbital
- Phenobarbital
- Rifampicin
- Carbamazepine
- Phenytoin
- St. John's Wort
Key clinical trials
- A Phase 2/3 Study in Adult and Adolescent Participants With SCD (PHASE2, PHASE3)
- GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) (PHASE2, PHASE3)
- A GBT021601 ADME Microtracer Study in Healthy Volunteers (PHASE1)
- Study of GBT021601 in Participants With Renal Impairment (PHASE1)
- A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD) (PHASE1)
- A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gbt021601 CI brief — competitive landscape report
- Gbt021601 updates RSS · CI watch RSS
- Pfizer portfolio CI